T1	Participants 91 124	low-grade non-Hodgkin's lymphoma:
T2	Participants 278 365	low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease
T3	Participants 394 548	70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week)
T4	Participants 556 577	63 evaluable patients
